The aim of the current prospective cohort study in this context is to assess how the severity of symptoms and the outcome of COVID-19 can be controlled and improved when IL-1 antagonist anakinra and IL-6 antagonist tocilizumab are prescribed early to individuals with mild to moderate cases. Here, IL6 is linked to COVID-19.